ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 468,53
0,42%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Acrivon Therapeutics Inc (ACRV)

  7. Acrivon Therapeutics Inc (ACRV) Actualités

ACRV Acrivon Therapeutics Inc

7,25
-0,47 (-6,09%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Acrivon Therapeutics Inc ACRV NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,47 -6,09% 7,25 06:00:01
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
7,65 7,10 7,73 7,25 7,72
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
29/5/202414:00GLOBEAcrivon Therapeutics to Present at the Jefferies Global..
21/5/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202401:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202401:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202401:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202401:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202400:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202400:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/5/202400:52EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/5/202414:00EDGAR2Form 8-K - Current report
14/5/202414:00GLOBEAcrivon Therapeutics Reports First Quarter 2024 Financial..
14/5/202413:31EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24/4/202422:01GLOBEAcrivon Therapeutics Reports Initial Positive Clinical Data..
17/4/202402:01GLOBEAcrivon Therapeutics to Host Corporate R&D Event..
10/4/202414:00GLOBEAcrivon Therapeutics Presents Data at AACR Annual Meeting..
09/4/202413:00GLOBEAcrivon Therapeutics Announces $130 Million Private..
28/3/202413:00GLOBEAcrivon Therapeutics Reports Fourth Quarter and Full Year..
06/3/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:29EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/3/202422:30GLOBEAcrivon Therapeutics to Present Data at AACR Annual Meeting..
04/3/202414:15EDGAR2Form 8-K - Current report
04/3/202414:00GLOBEAcrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA,..
27/2/202414:00GLOBEAcrivon Therapeutics to Participate in a Panel Discussion at..
16/2/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202421:40EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202414:27EDGAR2Form 8-K - Current report
08/2/202414:00GLOBEAcrivon Therapeutics Appoints Seasoned Industry Executive..
06/2/202414:00GLOBEAcrivon Therapeutics to Present at the Oppenheimer 34th..
19/1/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202422:00GLOBEAcrivon Therapeutics Announces Inducement Grants Under..
08/1/202413:28EDGAR2Form 8-K - Current report
04/1/202414:00GLOBEAcrivon Therapeutics to Present at the 42nd Annual J.P...
18/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
08/12/202322:21EDGAR2Form 8-K - Current report
01/12/202322:35EDGAR2Form S-3 - Registration statement under Securities Act of..
28/11/202314:58DJNAcrivon Therapeutics Gets FDA's Breakthrough Designation for..
28/11/202314:00GLOBEAcrivon Therapeutics Announces FDA has Granted Breakthrough..
21/11/202314:00GLOBEAcrivon Therapeutics to Present at the Piper Sandler Annual..
17/11/202301:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

NASDAQ
ACRV
Acrivon Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés